Disclaimer: The Views/Opinions expressed and/or opinions provided in Videos and other content on MedEnrich Website are those of respective speakers. They do not purport to reflect the opinion or views of Dr.Reddy’s Laboratories Limited or its affiliates (collectively Dr.Reddy’s)in any manner whatsoever and accordingly ,Dr.Reddys does not recommend , endorse or make any representation about the veracity and appropriateness of the views ,opinions/ information on MedEnrich website. Content on MedEnrich website may discuss uses and dosage for therapeutic product that may not have been approved in by the relevant regulatory agencies in your country. Dr.Reddy’s does not support , endorse or encourage any off-label use. Please refer to approved label before prescribing.
Content
Myelodysplastic Syndromes
10m 25s
Recommendations to improve Real World outcomes in MDS patients
Published 11 Jul 2022
Cytogenetic heterogeneity like deletion in chromosome 5, 7 and Trisomy 8 are increasingly observed in patients with Myelodysplastic Syndromes. Genetic mutations like ASXL1 & TET2 are increasingly found in patients with MDS.